secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2023-06-07T23:59:59+00:00
Accession:  0001178913-23-002176
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio appoints Haya Taitel to Board of Directors, Class II
---------------------------------------------------------------

- Board expanded Class II from one to two directors; Taitel appointed June 4, 2023, term through 2025 annual meeting.
- Taitel is Head of Sanofi's Global Transplant Franchise; previously Kadmon CCO (Rezurock launch) and Johnson & Johnson leader.
- Board determined Taitel independent under SEC and Nasdaq rules; no material transactions with company.
- Taitel to receive standard non-employee director compensation (cash retainers + annual option grants under 2018 plan).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891323002176/0001178913-23-002176-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891323002176/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001178913-23-002176

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer